These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31407377)

  • 1. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.
    Coleman CI; Weeda ER; Kharat A; Bookhart B; Baker WL
    Diabet Med; 2020 Jan; 37(1):44-52. PubMed ID: 31407377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive agents for preventing diabetic kidney disease.
    Lv J; Perkovic V; Foote CV; Craig ME; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD004136. PubMed ID: 23235603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.
    Hiremath S; Fergusson DA; Fergusson N; Bennett A; Knoll GA
    Am J Kidney Dis; 2017 Jan; 69(1):78-86. PubMed ID: 27712852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
    Shunan F; Jiqing Y; Xue D
    J Renin Angiotensin Aldosterone Syst; 2018; 19(4):1470320318803495. PubMed ID: 30296880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
    Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
    Diabetes Res Clin Pract; 2013 Dec; 102(3):233-41. PubMed ID: 24183258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
    Garg J; Bakris GL
    Curr Hypertens Rep; 2002 Jun; 4(3):185-90. PubMed ID: 12003699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
    Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.